Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Loqus23 Therapeutics Ltd.
BioCentury | Feb 22, 2025
Discovery & Translation
Science Spotlight: Bacterial payload delivery from nose to brain
BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells
BioCentury | Feb 19, 2025
Management Tracks
Mehta named CMO, Greenberg CBO at Nura Bio
Plus: Shawnte Mitchell joins Olema as chief legal and updates from Loqus23, Pheast, Crafton, Eupraxia and more
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: New protein degradation mechanism
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Oct 14, 2023
Emerging Company Profile
AstronauTx: targeting astrocytes to treat neurodegenerative diseases
London, U.K.-based company aims to clear a wide array of toxic proteins out of the brain, and is settings it first sights on Alzheimer’s disease
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Mar 19, 2022
Emerging Company Profile
LoQus23: going upstream to slow Huntington’s disease
By targeting the DNA damage repair pathway, the U.K. biotech hopes to stop the formation of mutated HTT, not clean it up afterwards
BioCentury | Nov 24, 2021
Product Development
Nov. 23 Quick Takes: Aadi’s Fyarro approved for rare sarcoma
Plus BMS’s Zeposia, LoQus23’s seed round, Simcere’s COVID antiviral and more
BioCentury | Jun 18, 2021
Finance
Dementia Discovery Fund’s investments: Data Byte
Since its launch by SV Health Investors in 2015 to fund new thinking in Alzheimer’s and other neurological diseases, Dementia Discovery Fund (DDF) has funded one to four companies per year
Items per page:
1 - 9 of 9